Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform


Out of Business LATEST DEAL TYPE

Developer of next generation gene expression systems designed to solve problems in molecular therapeutics. The company's gene expression systems are developed with genetically engineered CHO cells and also provides services like gene cloning, codon optimization, gene synthesis, cell culture scale up, cell based assays and fow cytometry, enabling physicians to kill cancer cells with the highest possible efficiencies while leaving normal cells unharmed.

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Primary Office
  • 9700 Great Seneca Highway
  • Suite 191
  • Rockville, MD 20850
  • United States

+1 (301) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Rafagen’s full profile, request a free trial.

Rafagen Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Aug-2016 00000 Completed Out of Business
4. Grant 04-Nov-2010 00000 Completed Startup
3. Corporate 16-Dec-2009 00000 Completed Startup
2. Early Stage VC 01-Apr-2009 $237K Completed Startup
1. Accelerator/Incubator 09-Jul-2008 $237K $237K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Rafagen Executive Team (3)

Name Title Board
Sung Hahm Ph.D Co-Founder, President & Chief Executive Officer
Ja Koo Ph.D Co-Founder & Chief Technology Officer

1 Former Executive

You’re viewing 2 of 3 executives. Get the full list »